List view / Grid view
28 June 2016 | By Victoria White, Digital Content Producer
If approved by the EMA and FDA for both indications, Ocrevus would be the first and only treatment for both forms of multiple sclerosis...
The European Commission has approved Roche’s Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma.
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...
8 June 2016 | By Victoria White, Digital Content Producer
The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations...
The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia...
27 May 2016 | By Victoria White, Digital Content Producer
Roche has announced positive results from the pivotal Phase III GALLIUM study.
24 May 2016 | By Victoria White, Digital Content Producer
Lariam, the anti-malarial drug sometimes prescribed to British troops, should be considered only as a drug of last resort, says the Defence Committee...
20 May 2016 | By Katie Sadler
Roche has announced that Alecensa, an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death in Japanese people with advanced or recurrent, ALK-positive non-small cell lung cancer (NSCLC).
11 April 2016 | By Victoria White, Digital Content Producer
The FDA has granted a priority review for atezolizumab for the treatment of locally advanced or metastatic NSCLC that expresses the protein PD-L1...
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
29 February 2016 | By Victoria White
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab...
17 February 2016 | By Victoria White
Roche's ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis...
10 February 2016 | By Victoria White
The study showed that patients with NSCLC lived significantly longer without disease worsening when treated with Alecensa compared to crizotinib...
28 January 2016 | By Victoria White
The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
